Argonaute RNA

Argonaute RNA is a biopharmaceutical company developing small interfering RNA therapeutics for cardiovascular disease.

Its siRNA platform uses proprietary chemical stabilisation to enable safe, targeted and temporary gene silencing in specific tissue cells, overcoming delivery and safety barriers that have constrained earlier siRNA approaches.

The lead programme targets severe familial hypercholesterolaemia, with a dual siRNA platform also in development for complex multifactorial conditions.